All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

How does COVID-19 impact patients with lymphoma receiving B-cell-depleting immunotherapy?

During the EHA2021 Virtual Congress, the Lymphoma Hub spoke with Caroline Besson, Université de Paris, Paris, FR. We asked, How does COVID-19 impact patients with lymphoma receiving B-cell-depleting immunotherapy?

How does COVID-19 impact patients with lymphoma receiving B-cell-depleting immunotherapy?

In this video, Besson discusses the outcomes of a trial looking at patients with lymphoma and COVID-19 infection, including duration of hospitalization, mortality rates, and comorbidities.

 

Share: